Review articlePublished 2014

Targeting the PI3K/AKT Pathway for the Treatment of Gastric Cancer

Authors: Yuyan Liu, Sunrong Sun, Juanjuan Li, De-Hua Yu

Chemotherapy: Open Access

Volume 3 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Gastric Cancer (GC) is the fourth most common malignancy and the second leading cause of cancer deaths,accounting for 10% of global cancer mortalities. Despite the progress made in recent years, the prognosis forpatients with advanced-stage GC remains poor. In the metastatic setting, chemotherapy is the primary choice forpalliative therapy and results in Objective Response Rates (ORRs) of only 20-40% and median Overall Survivals(OSs) of 8–10 months. Emerging evidence suggests that the aberrant activation of phosphatidylinositol 3-kinase(PI3K)/AKT signaling is one of the most common molecular events involved in the resistance to current systemictherapies for GC.A number of small molecule inhibitors targeting the PI3K/AKT pathway are currently under clinicalevaluation for the treatment of various malignancies, including GC. In this paper, we review the current clinicalpractice and discuss the potential use of inhibitors targeting the PI3K/AKT pathway, either alone or in combinationwith current therapies for the treatment of advanced GC.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalChemotherapy: Open Access
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Yuyan Liu”
  • BylineArticles whose byline prints “Sunrong Sun”
  • BylineArticles whose byline prints “Juanjuan Li”
  • BylineArticles whose byline prints “De-Hua Yu”